Podcasts about er pr

Proceedings from the first in a series of 11 summer webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Ms Allie Hershey and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Management of Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (11:54) Case: A woman in her early 40s with ER/PR (progesterone receptor)-positive, HER2-negative, node-positive breast cancer — Sara M Tolaney, MD, MPH (12:39) Case: A woman in her early 60s with hormone receptor-positive, node-positive breast cancer —Allie Hershey, MSN, RN, ANP-BC, AOCNP (19:23) Treatment of HER2-Positive Breast Cancer (30:44) Case: A woman in her mid-40s with hormone receptor-positive, HER2-positive metastatic breast cancer — Ms Hershey (32:29) Case: A woman in her mid-30s with ER-positive, HER2-positive metastatic breast cancer — Dr Tolaney (42:16) Clinical Considerations for Patients with Triple-Negative Breast Cancer (TNBC) (48:06)  Case: A woman in her early 50s with metastatic TNBC — Ms Hershey (49:27) CME information and select publications

Proceedings from the first in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Carey K Anders, Kathy D Miller and Sara M Tolaney on cases from the practices of Ms Gretchen Santos Fulgencio, Ms Allie Hershey and Ms Kelly Leonard, including the following topics: Introduction (0:00) Management of Estrogen Receptor (ER)-Positive Breast Cancer (9:58) Case: A woman in her early 30s with localized ER/progesterone receptor (PR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and 3 positive nodes — Gretchen Santos Fulgencio, MSN, FNP-BC (10:31) Case: A woman in her early 50s with ER-positive, HER2-negative metastatic breast cancer and a PIK3CA tumor mutation — Kelly Leonard, MSN, FNP-BC (31:34) Treatment of HER2-Positive Breast Cancer (41:14) Case: A woman in her early 30s with localized ER/PR-positive, HER2-positive breast cancer and residual disease after neoadjuvant treatment — Ms Leonard (41:29) Case: A woman in her early 70s with metastatic HER2-positive breast cancer — Ms Fulgencio (53:16) Case: A woman in her mid-40s with ER/PR-positive, HER2-positive metastatic breast cancer — Allie Hershey, MSN, RN, ANP-BC, AOCNP (1:02:04) Case: A woman in her mid-60s with ER-positive, HER2-positive metastatic breast cancer and brain metastases — Ms Leonard (1:13:44) Care of Patients with Triple-Negative Breast Cancer (TNBC) (1:18:33) Case: A woman in her early 50s with metastatic BRCA wild-type TNBC, PD-L1-positive — Ms Hershey (1:19:14) NCPD information and select publications

Featuring an interview with Dr Adam M Brufsky, including the following topics: Personalized medicine for HER2-positive early breast cancer (0:00) Case: A woman in her early 60s with ER/PR-positive, HER2-positive invasive ductal carcinoma who receives T-DM1 and neratinib (21:40) Case: A woman in her mid-40s with ER/PR-positive, HER2-positive early breast cancer (23:48) Case: A woman in her late 50s with ER/PR-negative, HER2-positive early breast cancer (26:10) CME information and select publications

Proceedings from the second in a 2-part nursing webinar series. Featuring perspectives from Ms Jamie Carroll and Dr Sara Hurvitz, including the following topics: Introduction (0:00) An Overview of Breast Cancer in 2021 Case: A premenopausal woman in her early 40s with ER-positive, HER2-positive, node-negative breast cancer — Laurie Matt Amaral, MD, MPH (3:17) Management of Localized HER2-Positive Breast Cancer (7:22) Case: A woman in her early 70s with clinical T4 ER/PR-negative, HER2-positive breast cancer —Dr Matt Amaral (11:35) Sequencing of Agents for Metastatic HER2-Positive Breast Cancer (14:57) Case: A woman in her early 70s with a 10-cm Grade III, ER/PR-negative, HER2-positive infiltrating ductal carcinoma and pleural metastases — Alan B Astrow, MD (30:30) Case: A woman in her mid-30s with heavily pretreated ER/PR-positive, HER2-positive breast cancer and bone metastases — Estelamari Rodriguez, MD, MPH (36:34) Systemic Treatment of Brain Metastases in Patients with HER2-Positive Breast Cancer (51:33) Case: A Middle Eastern woman in her early 40s with HER2-positive breast cancer and brain metastases — Yanjun Ma, MD (51:49) Case: A woman in her early 40s with ER/PR-negative, HER2-positive breast cancer with brain metastasis — Atif Hussein, MD, MMM (55:06) NCPD information and select publications

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Genomic assays in early-stage breast cancer (0:00) Case: A woman in her early 30s with a family history of breast cancer is diagnosed with hormone receptor (HR)-positive disease and receives a 21-gene assay Recurrence Score® (RS) of 16 (35:08) Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer and a 21-gene RS of 11 receives a recommendation of radiation therapy and an aromatase inhibitor (38:45) Case: A woman in her mid-20s with ER-positive, PR-negative, HER2-negative breast cancer and axillary involvement receives a MammaPrint® high score (40:42) Design and key findings of the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative early breast cancer with 1 to 3 positive lymph nodes and a 21-gene RS of 25 or lower (43:42) Benefit of chemotherapy for premenopausal versus postmenopausal patients enrolled in the RxPONDER trial (47:15) Predictors of late recurrence; use of ctDNA (circulating tumor DNA) as a biomarker of recurrence (51:40) Utility of the RSClin educational tool integrating the 21-gene RS and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit for patients with HR-positive, HER2-negative, node-negative breast cancer (56:59) Impact of the COVID-19 vaccine on screening for breast cancer (1:00:30) Perspective on the use of genomic assays in the neoadjuvant setting (1:02:41) Age-associated benefit from chemotherapy for women with luminal breast cancer in the MINDACT trial (1:06:53) CME information and select publications

Featuring perspectives from Dr Mark D Pegram on the following topics: Case presentations and San Antonio Breast Cancer Symposium (SABCS®) review of locally advanced and high-risk HER2-positive breast cancer Introduction (0:00) Case: A 49-year-old woman who received neoadjuvant TCHP, currently awaiting surgery — Estelamari Rodriguez, MD, MPH (5:12) Case: A 55-year-old woman with Stage I HER2-positive breast cancer — Kelly Yap, MD (23:46) Case: A 45-year-old woman who received postoperative T-DM1 after neoadjuvant TCHP — Philip Glynn, MD (26:30) Case: A 39-year-old woman with localized disease and a positive cervical node on PET scan — Dr Rodriguez (32:00) Case presentations and SABCS review of metastatic HER2-positive breast cancer Case: A 70-year-old woman with a 10-cm Grade III, ER/PR-negative, HER2-positive infiltrating ductal carcinoma and pleural metastases — Alan B Astrow, MD (38:24) Case: An 87-year-old woman with pretreated HER2-positive metastatic breast cancer now with negative (low) HER2 — Yanjun Ma, MD (43:25) Case: A 60-year-old woman with malignant pericardial effusion — Dr Glynn (50:23) Case: A 43-year-old woman who develops brain metastases after prior TCHP — Dr Yap (53:09) CME information and select publications

Aion Therapeutic Inc's (CSE:AION) Dr. Stephen Barnhill tells Proactive that the group's proprietary and patented combinatorial mushroom preparations, AION F7 and AION F8, showed high efficacy in killing multiple types of breast cancer cells. Dr Barnhill says the preparations demonstrated direct killing of HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity, a similar effectiveness as trastuzumab, an FDA approved monoclonal antibody treatment for HER2+ breast cancer sold under the brand name Herceptin.

Featuring a roundtable discussion with Drs Virginia F Borges, Sara Hurvitz and Ian E Krop, including the following topics: Introduction Impact of COVID-19 vaccinations on screening for breast cancer (0:00) Management of HER2-positive early breast cancer Case: A woman in her early 40s with ER/PR-positive, HER2-positive breast cancer achieves a pathologic complete response with docetaxel/trastuzumab/pertuzumab — Alan B Astrow, MD (6:30) Therapeutic approach for patients with HER2-positive breast cancer and residual disease after neoadjuvant therapy (10:04) Case: A woman in her early 70s with Grade III, ER/PR-negative, HER2-positive breast cancer develops shortness of breath after neoadjuvant chemotherapy — Dr Astrow (19:57) Disease-specific factors in the selection of neoadjuvant therapy for patients with HER2-positive breast cancer (28:00) Selection of HER2-targeted therapy in the adjuvant setting  (33:31) Selection and sequencing of therapies for HER2-positive metastatic breast cancer Case: A woman in her early 40s with HER2-positive breast cancer and brain metastases — Yanjun Ma, MD (36:11) Case: A woman in her mid-30s with ER/PR-positive, HER2-positive breast cancer and brain metastases — Estelamari Rodriguez, MD, MPH (40:56) Case: A woman in her mid-60s who presents with a large, ulcerated breast mass and is diagnosed with HER2-positive breast cancer and liver metastases — Dr Astrow (48:38) Choice of initial therapy for patients with metastatic HER2-positive breast cancer (55:08) Management of HER2-positive breast cancer with brain metastases; intracranial activity of tucatinib in patients with metastatic HER2-positive breast cancer (1:00:00) CNS penetration and intracranial response with the antibody-drug conjugates trastuzumab deruxtecan and T-DM1; efficacy and tolerability of neratinib after disease progression on tucatinib (1:07:28) Perspective on the use of hormonal therapy for patients with ER/PR-positive, HER2-positive breast cancer (1:12:45) Efficacy of PARP inhibitors in patients with HER2-positive breast cancer and BRCA mutations; emerging data from the OlympiA trial evaluating olaparib as adjuvant therapy for patients with HER2-negative breast cancer and germline BRCA mutations (1:18:53) Benefits and risks of the novel anti-HER2 antibody margetuximab for patients with HER2-positive advanced breast cancer (1:25:10) CME information and select publications

Proceedings from the first of 2 sessions on HER2-positive breast cancer. Featuring perspectives from Dr Erika Hamilton, including the following topics: Introduction and review of SABCS 2020 Educational Session on HER2-targeted therapy (0:00) Case: A 42-year-old premenopausal woman with ER-positive, HER2-positive, node-negative breast cancer — Laurie Matt-Amaral, MD, MPH (7:59) SABCS 2020 Review (22:55) Case: A 43-year-old woman with ER/PR-negative, HER2-positive breast cancer with brain metastasis — Atif Hussein, MD, MMM (28:00) Case: A 73-year-old woman with clinical T4 ER/PR-negative, HER2-positive breast cancer — Dr Matt-Amaral (43:30) Case: A 36-year-old physician with ER/PR-negative, HER2-positive, node-positive breast cancer during pregnancy — Dr Hussein (51:12) CME information and select publications

FDA 批准一种新型的单抗-药物偶联物治疗乳腺癌JAMA 乳腺癌筛查时，简易乳房MRI与数字乳房合成技术哪一种好？Science子刊 能快速诊断癌症的便携式细胞分析仪-CytoPAN曲妥珠单抗-德鲁替康（trastuzumab deruxtecan）曲妥珠单抗-德鲁替康（trastuzumab deruxtecan）是一种HER-2单抗、偶联拓扑异构酶1抑制剂的药物。2019年12月，曲妥珠单抗-德鲁替康（trastuzumab deruxtecan）被FDA批准用于治疗HER2阳性的、经治疗的乳腺癌。《DESTINY-Breast01研究：曲妥珠单抗-德鲁替康经治疗的HER2阳性乳腺癌的2期临床研究》New England Journal of Medicine，2020年2月 (1)这项2部分的、开放标签、单组、多中心、2期研究，评估了184名、HER2阳性的、转移性乳腺癌患者，使用曲妥珠单抗德鲁替康的疗效。研究第一部分，使用了3种不同剂量，以确定推荐剂量；在第二部分中，评估了推荐剂量的有效性和安全性。曲妥珠单抗德鲁替康的推荐剂量为5.4mg/kg。随访11.1个月后，患者的中位缓解时间为14.8个月，中位无进展生存时间为16.4个月。在研究中，最常见的严重不良事件是中性粒细胞计数减少、贫血和恶心。结论：曲妥珠单抗-德鲁替康在HER2阳性的、转移性乳腺癌患者中，显示出持久的抗肿瘤活性。除了恶心和骨髓抑制，治疗组还观察到间质性肺病，因此用药过程中需监测肺部情况。避孕法避孕法主要包括激素避孕和非激素避孕。激素避孕药包括雌-孕激素避孕药和单纯孕激素避孕药；可采用口服、注射、皮下植入剂、透皮贴剂、子宫避孕器或阴道避孕器等方式给药。非激素避孕法主要包括：输卵管阻断、含铜宫内避孕器、避孕套。《回顾性研究：避孕法类型是否影响痤疮的发病率和严重程度》Obstetrics and Gynecology，2020年5月 (2)皮肤科医生常开出复方口服避孕药用于治疗痤疮，这项回顾性队列研究，目的是比较各种避孕法使用1年内，对痤疮的发病率和严重程度的影响。研究共大约337,000名避孕法的新使用者（年龄12～40岁），2%～8%出现新发痤疮，年轻女性的发病率较高。研究发现复方口服避孕药相比，含铜宫内节育器的痤疮发生风险比为1.14，含孕酮的宫内节育器的痤疮风险比1.09，这些女性新发痤疮后的就诊率略高。21,000名患有痤疮病史的女性，使用含铜宫内节育器和含孕酮的节育器后，从外用药转换成口服四环素类抗生素的可能性更高（风险比分别为1.44和1.34）。结论：复方口服避孕药似乎痤疮风险相对较小，各种避孕法之间绝对差异也很小。 《回顾性研究：产后即刻行皮下植入依托孕烯植入剂避孕，与静脉血栓栓塞的关系》Obstetrics and Gynecology，2020年6月 (3)来自贝勒大学医学院的研究人员，对分娩后30天内皮下植入依托孕烯植入剂的妇女与未植入的妇女的再入院率进行了比较，旨在明确这种避孕方法是否增加静脉血栓的风险。在338万余名产妇中，排除有静脉血栓栓塞史或抗凝治疗史的产妇，共8369名产妇在分娩住院期间接受了皮下植入避孕。研究发现，依托孕烯避孕的产妇和没有避孕的产妇的静脉血栓栓塞再入院率没有差异；而且糖尿病、血栓性血友病、系统性红斑狼疮和剖宫产的发生率在组间无差异。统计发现，接受避孕植入的产妇更年轻、收入更低、吸烟者更多、高血压、围产期感染或产后出血发生率也较高；在对这些混杂因素进行调整后，静脉血栓栓塞发生率的风险比为1.81，没有统计学差异（95%可信区间0.44 - -7.45）。结论：分娩后立即接受依托孕烯避孕植入物避孕，没有增加静脉血栓发生率。《对照研究：依托孕烯避孕植入物使用者不良出血模式的治疗》Obstetrics and Gynecology，2020年8月 (4)依托孕烯避孕植入物的主要副作用是阴道不规则出血，该研究的目的是评价短程使用他莫西芬是否有效。这个研究的前90天，这是一个双盲、随机、对照试验中，研究纳入112名植入依托孕烯避孕植入物后反复阴道出血的女性，随机双盲入组他莫昔芬10mg bid组或安慰剂组，连续治疗7天。然后，参与者进入下一个90天的开放标签研究，如果需要每30天可以接受最多3个疗程的他莫西芬，在此期间，参与者使用短信记录每天的流血情况。双盲对照期间，他莫西芬组报告在最初90天内阴道连续不出血的天数比安慰剂组少9.8天（P=0.001)；在开放标签阶段，服用他莫西芬的女性得到了类似的疗效。在随机对照期，他莫西芬组参与者的满意度也更高。结论：短疗程的他莫昔芬减少了问题性出血，提高了使用者的满意度。《随机对照研究：新型的宫内节育器的2期临床研究》Obsteteric & Gynecology，2020年4月 (5)这种新型的宫内节育器，支架含有镍钛合金，铜仅位于靠近子宫角和子宫颈内口的位置，含有的铜和镍钛合金的剂量都很小；而且设计时为了方便放置，自带细线。因此，这种宫内节育器可能减少与铜相关的子宫痉挛和出血。在这项为期36个月2期研究中，纳入了286名女性，评价了总共5,640个月经周期的妊娠情况。宫内节育器的平均使用时间为2.7年；37.8%的女性使用该宫内节育器的时间达到36个月。在使用宫内节育器的第1年，每个月经周期的平均出血天数从7.6天（第1个月经周期）减少至5.2天（第13个月经周期）。主要不良反应是出血、疼痛。结论：这种新型的宫内节育器有效性高，且耐受性好。《系统回顾：延长宫内节育器使用时间的有效性和安全性》American Journal of Obstetrics and Gynecology，2020年7月 (6)文章系统地回顾了关于宫内节育器超过批准的有效时间后，是否仍能有效和安全的避孕。研究纳入了2篇关于含铜宫内节育器（批准有效期10年）和4篇关于左炔诺孕酮宫内节育器（批准有效期为5年）的研究。研究发现，左炔诺孕酮宫内节育器在第6和第7年合并妊娠率为0.02/100人年(95%置信区间，0.00-0.29)。超期使用后，每年不良事件发生率、或因不良事件取环的比率为0- 3.7/100。对于含铜宫内节育器，11年和12年的合并妊娠率为0.0/100人年(95%可信区间为0-0.8)；在此期间，不良事件年发生率为0-4.6/100人。结论：左炔诺孕酮宫内节育器和含铜宫内节育器，延长使用的前两年的妊娠率、不良事件率、因副作用取出率都是很低的；但这些数据在数量和质量上都是有限的，不建议推广。乳腺癌的筛查乳腺癌的筛查首先需要对风险进行分层。没有卵巢癌、腹膜癌、乳腺癌个人史或家族史，没有遗传基因突变，10-30岁之间没有接受过胸部放疗的女性属于低危人群；有以上病史的女性属于高危。美国癌症协会建议女性45岁开始接受每年一次的钼靶筛查，55岁以后每两年一次。筛查方式：钼靶是首选，高危女性可使用MRI联合钼靶。《横向研究：简易乳房MRI与数字乳房合成技术在筛查致密乳房女性中乳腺癌的比较》JAMA，2020年2月 (7)乳腺密度高的女性患乳腺癌的风险增加，研究旨在比较简易乳房MRI和数字乳房合成技术对致密乳腺患者的筛查效果。共1516名女性参与了研究，平均年龄54岁。队列中，有17名浸润性乳腺癌和6名原位导管癌。MRI检测出全部17名浸润性乳腺癌和5名原位导管癌；数字合成技术仅检测出7例浸润性乳腺癌和2例原位癌。MRI敏感度为95.7%、特异性为86.7%；数字合成技术灵敏度为39.1%，特异性为97.4%（P=0.001，P

Октябрь — это Месяц повышения осведомленности в отношении рака молочной железы. В рамках подкаста «Я и оно: как пережить онко» автор Яна Седова вместе с приглашенными специалистами рассказывает об особенностях этого заболевания и о современных методах лечения. В этом выпуске вместе с онкохирургом и маммологом Артемом Федосовым Яна разбирается в том, как правильно читать диагноз при раке молочной железы. Как сегодня стадируют рак, что такое Ki67 и показатели TNM и G, как на прогноз влияет HER2 (human epidermal growth factor receptor 2) и эстрогены и прогестерон (ER и PR), какие обследования показаны при подозрении на РМЖ и какие следует проходить по окончании системного лечения — слушайте в этом эпизоде подкаста. *** Станьте частью сообщества друзей hromadske — поддержите наши проекты любой суммой на платформе Спільнокошт! biggggidea.com/project/spilnota-druziv-hromadske/

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.   These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.   In this episode of HOPA Now, Dr. Neelam Patel details the epidemiology, pathophysiology, and staging of breast cancer, one of the most commonly diagnosed cancers in American women. She offers data, diagnosis percentages, and survival rates for breast cancer patients; shares common risk factors, presentation, and common histologies of breast cancer; and details prognostic factors and recent changes to adjuvant treatment guidelines.   In this episode you will learn:   Breast Cancer Fundamentals Data, diagnosis percentages, and survival rates surrounding breast cancer Common germline mutations in breast cancer patients Risk factors regarding breast cancer, including gender, family history, and estrogen exposure Common presentation of breast cancer masses and common histologies of breast cancer Tumor size, nodal status, and presence of metastatic disease and other prognostic factors including ER/PR and HER2 status and grade of tumors Recent changes to adjuvant treatment guidelines   Mentioned in This Episode: HOPA   Quotes:   “Breast cancer masses usually present as a painless lump that is self-detected or found on screening mammograms.” — Dr. Neelam Patel   “In recent years the AJCC updated their guidelines to include other prognostic factors such as ER/PR and HER2 status and grade of the tumor.” — Dr. Neelam Patel   “One thing to remember is this is a prognostic stage and is more to help the clinician and patient understand what their prognosis is, and does not necessarily dictate treatment.” — Dr. Neelam Patel  

A special video supplement to a CME conference held during the 2019 San Antonio Breast Cancer Symposium featuring expert comments on the management of ER-positive breast cancer. Featuring perspectives from Dr Harold J Burstein. Use of genomic classifiers to inform therapeutic decision-making for ER-positive localized breast cancer (00:00) Prognostic and/or predictive utility of the various genomic assays for patients with node-negative and node-positive early breast cancer (03:23) Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized breast cancer (05:27) Effects of prolonging adjuvant aromatase inhibitor therapy beyond 5 years on recurrence and cause-specific mortality (10:42) NSABP-B-42: Ten-year results of extended adjuvant endocrine therapy with letrozole for postmenopausal women with ER-positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor (AI) (12:28) Optimizing the use of CDK4/6 inhibitors in the management of ER-positive metastatic breast cancer (mBC); overall survival findings and mechanisms of resistance (14:56) Management of de novo ER-positive, HER2-negative mBC (18:22) Choice of endocrine therapy partner for patients with de novo ER-positive, HER2-negative mBC (21:39) Approach for patients with mBC and disease progression on an AI (24:04) Selection and sequencing of CDK4/6 inhibitors in mBC; comparison of side-effect profiles (26:40) Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC (31:35) Results of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with ER-positive, HER2-negative advanced BC with or without a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval for breast cancer with a PIK3CA mutation and current clinical role (33:27) Spectrum, frequency and severity of toxicities observed with alpelisib (36:09) Clinical experience with everolimus in mBC; potential for its use after disease progression on a CDK4/6 inhibitor (39:07) Biologic rationale for evaluation of the Bcl-2 inhibitor venetoclax in ER-positive mBC (40:54) Overview of the novel HER2-directed agents trastuzumab deruxtecan and tucatinib for HER2-positive mBC (44:00) Dual targeted approach for patients with ER/PR-positive, HER2-positive mBC (46:40) Investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway (50:06) Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role (51:08) Perspectives of Dr Burstein and Dr Love on the passing and legacy of the breast cancer revolutionary Dr Bernard Fisher (56:40) Advances in the adjuvant treatment of HER2-positive and triple-negative breast cancer (1:02:24) CME information and select publications

Jame Abraham, MD, of the Cleveland Clinic joins Blood & Cancer host David H. Henry, MD, of Pennsylvania Hospital, Philadelphia to review two cases of breast cancer, focusing on when to use the 21-gene Oncotype DX breast recurrence score and how to apply the results.   Plus, in Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, explores what happens when the patient minimizes their symptoms in order to keep getting treatment. *  *  *  Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 *  *  *  This Week in Oncology Not all lung cancer patients receive treatment By Richard Franki In the United States, just over 15% of patients with lung cancer receive no treatment, according to the American Lung Association. *  *  *  Breast cancer cases Case 1: A 46-year-old, premenopausal woman who has had a right breast lumpectomy with a 7-mm tumor that is invasive ductal, ER/PR positive, and HER2 negative. Since her tumor is small and low grade, would you do Oncotype DX recurrence score testing? Dr. Abraham recommends: Explain to the patient that her benefit from chemotherapy will be limited, but that she meets the tumor size requirement for the Oncotype DX assay and offer her the test. Case 2: A 57-year-old women who is postmenopausal with a grade 1 tumor that is 10mm, ER/PR positive, HER2 negative, with 4 of 17 positive lymph nodes. Is there an advantage to adding the Oncotype DX testing for this patient? Dr. Abraham recommends: Offer the patient chemotherapy; recommend against Oncotype DX testing. Show notes by Mary Ellen Schneider   References Sparano JA et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018 Jul 12;379(2):111-21. Sparano JA et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019 Jun 20;380(25):2395-2405. *  *  *  For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd Ilana Yurkiewicz on Twitter: @ilanayurkiewicz

Breast Cancer Update for Surgeons, Issue 1, 2019 — Part #1: Our interview with Dr Geyer highlights the following topics as well as cases from his practice: Case: A premenopausal woman in her mid-40s with Grade II, ER/PR-positive, HER2-negative lobular breast cancer, a 21-gene assay Recurrence Score (RS) of 10 and a deleterious CHEK2 mutation undergoes a bilateral mastectomy (00:00) Impact of gene-expression assay results on therapeutic decision-making  (04:54) Results of the Phase III TAILORx trial evaluating chemoendocrine therapy versus endocrine therapy alone for patients with ER-positive, HER2-negative, node-negative breast cancer and an intermediate RS (07:00) Clinical utility of the 21-gene and 70-gene assays (12:29) Benefit with the addition of ovarian function suppression to endocrine therapy for premenopausal women with ER-positive breast cancer at high risk for recurrence (14:11) Approach to assessing the adequacy of ovarian function suppression in premenopausal patients receiving aromatase inhibition (17:01) Significance of clinical risk category in prognosis and in the prediction of chemotherapy benefit by age and RS in the TAILORx trial (19:04) Use of adjuvant bone-modifying agents to reduce the risk of aromatase inhibitor-associated bone loss and fracture (24:51) Role of the 21-gene assay RS in guiding neoadjuvant therapy decision-making for ER-positive, HER2-negative localized breast cancer (27:39) Mechanism of action, efficacy and tolerability of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer (31:33) Investigation of CDK4/6 inhibitors alone or in combination with endocrine therapy in the neoadjuvant and adjuvant settings (36:00) Case: A postmenopausal woman in her mid-50s with Grade I, ER-positive, PR-negative, HER2-negative infiltrating ductal carcinoma (IDC) with 1 positive node and a RS of 20 receives an aromatase inhibitor and denosumab (39:49) Approach to the selection of adjuvant endocrine therapy; management of aromatase inhibitor-associated arthralgias (43:33) Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer (46:22) Prospective data with and ongoing evaluation of the 21-gene and 70-gene assays for patients with node-positive disease (49:23) Results from the Phase III KATHERINE study evaluating adjuvant T-DM1 versus trastuzumab for patients with HER2-positive localized breast cancer and residual disease after neoadjuvant treatment (54:20) Rationale for the design and entry criteria of the KATHERINE study (58:18) Mechanism of action, activity and tolerability of antibody-drug conjugates (1:02:46) Second opinion: Therapeutic options for a patient in her mid-40s with recurrent, locally advanced, ER/PR-positive, HER2-positive breast cancer (1:06:23) Clinical implications of the KATHERINE trial results (1:14:53) CME information and select publications  

Breast Cancer Update for Surgeons, Issue 1, 2019 — Part #2: Our interview with Dr King highlights the following topics as well as cases from her practice: Recent developments in the surgical care of patients with breast cancer (00:0s Predictive versus prognostic role of the 21-gene assay RS in ER-positive, HER2-negative, node-positive breast cancer (01:45) Clinical implications of the TAILORx trial results (05:11) Reliability of the 21-gene assay RS in guiding neoadjuvant therapy decision-making (07:19) Impact of genomic assay testing and clinical features on the use of chemotherapy after the implementation of standardized reflex testing criteria  (10:39) Clinical utility of the 21-gene assay RS in the selection of therapy  (15:34) Application and utility of the MINDACT trial results; use of the 70-gene signature assay in breast cancer  (17:48) Criteria for surgeon-initiated reflex gene-expression profile testing for patients with early-stage breast cancer to reduce delays in the initiation of chemotherapy  (19:26) Surgeon variability and factors predicting the need for reoperation after breast-conserving surgery (24:22) Recent trends in reoperation after initial lumpectomy for patients with breast cancer (26:45) Multidisciplinary management of the axilla for patients with breast cancer undergoing primary mastectomy (28:25) Optimal locoregional management of sentinel node-negative and node-positive breast cancer (31:54) Key issues regarding gross and microscopic evaluation of breast and lymph node specimens after neoadjuvant systemic therapy (36:36) Importance of accurate specimen evaluation in assessing treatment response (39:15) Factors predicting the use of preoperative therapy for young women with breast cancer; impact on breast-conserving surgery (41:55) Updated AJCC Staging Manual: Incorporation of tumor biology into breast cancer staging to tailor treatment and refine prognosis (43:46) Case: A woman in her mid-40s with ER/PR-negative, HER2-positive IDC receives neoadjuvant paclitaxel/trastuzumab/pertuzumab on the Phase I DAPHNe trial (47:22) Perspective on the results of the KATHERINE trial (52:52) Threshold for neoadjuvant therapy in triple-negative versus HER2-positive breast cancer; side-effect profile of paclitaxel in combination with trastuzumab and pertuzumab (54:51) Case: A woman in her mid-30s with triple-negative breast cancer has residual invasive disease in the breast and axillary lymph nodes after receiving neoadjuvant dose-dense AC followed by paclitaxel (56:49) Perspective on the importance of genomic testing in guiding treatment decision-making for patients with newly diagnosed disease (1:01:7s Surgical treatment options for patients with triple-negative breast cancer and germline BRCA mutations (1:03:20) Case: A woman in her mid-40s with ER/PR-positive, HER2-negative IDC receives a RS of 18 (1:05:37) Effects of age, menopausal status and RS on the prediction of benefit from chemotherapy (1:08:14) CME information and select publications  

A presentation from Dr O'Shaughnessy featuring emerging research and cases from her practice. Introduction (00:00) Program overview: Dr Love Estrogen and Progesterone Receptors; Clinical Use of Endocrine Treatment (1:20) Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer (BC) who experienced intolerable arthralgias with adjuvant aromatase inhibition and was switched to tamoxifen (7:08) First-Line Endocrine Therapy for Metastatic Disease: Role of CDK4/6 Inhibitors (12:44) Case: A woman in her mid-60s with ER/PR-positive de novo metastatic BC (mBC) who received palbociclib/letrozole (12:54) Case: A woman in her mid-50s with ER/PR-positive, HER2-negative BC who developed metastatic disease after receiving 4 years of adjuvant letrozole and started treatment with ribociclib/fulvestrant (27:39) Case: A woman in her early 60s who received abemaciclib/exemestane for ER/PR-positive, HER2-negative mBC to the brain and bone (33:09) Second-Line Endocrine Therapy for Metastatic Disease: Role of mTOR Inhibitors (42:18) Case: A woman in her late 60s with ER/PR-positive, HER2-negative mBC who received exemestane/everolimus after disease progression on a CDK4/6 inhibitor (42:26) New Approaches Under Investigation (51:47) Assessing and Optimizing Treatment Adherence (59:00) Case: A woman in her early 30s with ER/PR-positive, HER2-negative BC who demonstrated poor adherence to adjuvant endocrine therapy because of weight gain (59:09) Select publications  

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Fabrice André and Drs Virginia Kaklamani, Mark D Pegram, Hope S Rugo, Sara M Tolaney and Tiffany A Traina: Introduction Program overview: Dr Love (00:00) Available and Emerging Data Sets Shaping the Management of Localized HER2-Positive Breast Cancer (BC) Case (Dr Rugo): A woman in her mid-40s with ER/PR-negative, HER2-positive BC who received neoadjuvant TCHP and experienced a pathologic complete response (3:57) Case (Dr Rugo): A woman in her mid-50s with an ER-positive, HER2-positive infiltrating lobular carcinoma who received neoadjuvant chemotherapy/anti-HER2 therapy, had residual disease at surgery and initiated treatment with T-DM1 (6:39) Case (Dr Rugo): A woman in her early 40s with an ER-positive, HER2-positive IDC who received postadjuvant neratinib (11:42) Faculty Presentation: Dr Rugo (14:18) Use of Genomic Classifiers in Clinical Decision-Making for Patients with ER-Positive Early BC Case (Dr Kaklamani): A postmenopausal woman in her late 50s with an ER/PR-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® of 24 (38:46) Case (Dr Kaklamani): A postmenopausal woman in her mid-50s with an ER/PR-positive, HER2-negative IDC with 2 positive nodes and a 21-gene Recurrence Score of 21 (41:47) Faculty Presentation: Dr Kaklamani (48:39) Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic BC (mBC); Novel Agents and Strategies Under Evaluation in ER-Positive Disease Case (Prof André): A postmenopausal woman in her mid-50s who presented with ER/PR-positive, HER2-negative mBC approximately 2 years after the completion of adjuvant letrozole (1:07:13) Case (Prof André): A woman in her mid-70s with de novo ER/PR-positive, HER2-negative mBC with extensive liver involvement who received palbociclib/letrozole (1:10:03) Faculty Presentation: Prof André (1:11:05) Immunotherapy as a Rational Therapeutic Strategy in BC Case (Dr Tolaney): A woman in her early 60s with metastatic triple-negative BC (TNBC) who received atezolizumab/nab paclitaxel and remains NED 4 years later (1:28:14) Case (Dr Tolaney): A woman in her mid-60s with heavily pretreated TNBC who experienced a complete response to pembrolizumab but developed treatment-related diabetes and hypothyroidism (1:31:00) Faculty Presentation: Dr Tolaney (1:32:49) Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive mBC Case (Dr Pegram): A woman in her mid-60s with widespread ER-negative, HER2-positive mBC who received tucatinib/capecitabine/trastuzumab on a clinical trial (1:46:01) Faculty Presentation: Dr Pegram (1:47:28) Role of PARP Inhibitors, Novel Agents in mBC; Male Breast Cancer Case (Dr Traina): A woman in her early 60s with metastatic TNBC and a germline BRCA2 mutation who received olaparib monotherapy and achieved a complete response (2:11:31) Case (Dr Traina): A woman in her early 70s with metastatic androgen receptor-positive TNBC who received an investigational antiandrogen on a clinical trial (2:13:12) Case (Dr Traina): A man in his early 60s with ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation (2:16:16) Faculty Presentation: Dr Traina (2:18:32) Select publications

Video proceedings from the fifth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Erika Hamilton, Ms Elizabeth O'Reilly, Dr Hope S Rugo and Ms Gretchen Santos: Introduction (00:00) Program overview: Dr Love HER2-Positive Localized and Metastatic Breast Cancer (BC) (2:16) Case (Ms O'Reilly): A woman in her late 40s with ER-positive, HER2-positive Stage IIIB inflammatory BC who received neoadjuvant treatment, had significant residual disease at surgery and began adjuvant T-DM1 (9:04) Case (Ms Santos): A woman in her early 60s with ER-negative, HER2-positive BC who began 1 year of adjuvant trastuzumab/pertuzumab after mastectomy but was switched to T-DM1 (12:31) Case (Ms Santos): A woman in her early 40s with ER-positive, HER2-positive BC who received postadjuvant neratinib on the CONTROL study (38:38) Case (Ms O'Reilly): A woman in her early 60s initially diagnosed with ER-positive, HER2-negative BC presents with ER-positive, HER2-positive metastatic disease to the bone, liver and brain (43:41) ER-Positive, HER2-Negative Metastatic Disease (55:50) Case (Ms Santos): A premenopausal woman in her early 50s with widespread ER/PR-positive, HER2-negative metastatic BC to the bone who underwent ovarian ablation and received palbociclib/letrozole (1:5:38) Case (Ms O'Reilly): A woman in her early 50s with ER-positive metastatic BC who received multiple lines of systemic treatment, including abemaciclib monotherapy (1:15:53) Triple-Negative Metastatic BC (1:31:31) Case (Ms Santos): A woman in her mid-30s with metastatic triple-negative BC who experienced a good response to pembrolizumab (1:37:46) Select publications

Oncology Today with Dr Neil Love: Breast Cancer Edition — A virtual roundtable discussion with noted investigators Charles Geyer and Sara Tolaney for a review of recent innovations in breast cancer medicine: Design and results of the Phase III KATHERINE study investigating adjuvant T-DM1 versus trastuzumab for patients with residual invasive HER2-positive early breast cancer (0:00) Side effects and tolerability of T-DM1 compared to trastuzumab (3:00) Clinical implications of the KATHERINE trial (7:27) Case (Dr Geyer): A 53-year-old woman with a locally advanced ER/PR-negative, HER2-positive, ulcerated infiltrating ductal carcinoma (IDC) experiences neuropathy after 6 cycles of neoadjuvant TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab) (12:52) Management of the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy (15:36) Case (Dr Tolaney): A 56-year-old woman with a 3.7-cm ER/PR-negative, HER2-positive IDC receives neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab) and adjuvant AC followed by trastuzumab/pertuzumab (20:01) Selection of (neo)adjuvant treatment for patients with HER2-positive breast cancer (22:14) Optimal treatment for early-stage HER2-positive breast cancer (28:05) Role of the recently FDA-approved subcutaneous formulation of trastuzumab alone or in combination with chemotherapy for patients with HER2-positive BC (32:01) Final results from the OlympiAD trial of olaparib versus standard chemotherapy; results from the EMBRACA trial comparing talazoparib to standard therapy for patients with germline BRCA mutations (34:52) Case (Dr Geyer): A 31-year-old woman with metastatic ER/PR-positive, HER2-negative breast cancer receives ovarian suppression, fulvestrant and abemaciclib (39:45) Use of PARP inhibitors for patients with metastatic breast cancer and BRCA mutations (41:51) Case (Dr Tolaney): A 59-year-old woman with ER/PR-positive, HER2-negative metastatic breast cancer and a BRCA2 mutation receives olaparib as second-line therapy (45:18) Sequencing of PARP inhibitors for patients with metastatic triple-negative breast cancer (TNBC) and BRCA mutations (49:52) Ongoing PARTNER/PARTNERING studies evaluating olaparib with platinum-based neoadjuvant chemotherapy or as a part of novel combination approaches; investigation of neoadjuvant talazoparib for patients with TNBC and a germline BRCA mutation (51:49) Ongoing Phase III OlympiA trial evaluating olaparib as adjuvant treatment for high-risk, HER2-negative breast cancer with a germline BRCA mutation (54:33) Efficacy and safety of atezolizumab with nab paclitaxel for advanced TNBC in the Phase III IMpassion130 trial (56:57) Choice of chemotherapy for patients with metastatic TNBC (59:49) Perspective on overall survival for patients with advanced TNBC and PD-L1-positive tumors treated with atezolizumab and nab paclitaxel (1:4:42) Case (Dr Tolaney): A 52-year-old woman develops pneumonitis while receiving pembrolizumab and eribulin for metastatic TNBC (1:7:09) Endocrine toxicities associated with immune checkpoint inhibitors (1:9:26) Ongoing Phase III NSABP-B-59/GBG-96-GeparDouze trial evaluating neoadjuvant chemotherapy with atezolizumab followed by adjuvant atezolizumab (1:10:34) Ongoing Phase III ALEXANDRA/IMpassion030 study evaluating standard adjuvant chemotherapy with or without atezolizumab for early TNBC (1:13:10) Emerging data with the HER2-selective tyrosine kinase inhibitor tucatinib for advanced HER2-positive metastatic breast cancer (1:14:48) Comparison of the activity and tolerability of tucatinib to that of lapatinib and neratinib (1:19:15) Efficacy and safety of the novel antibody-drug conjugate trastuzumab deruxtecan for HER2-positive breast cancer (1:21:46) Results of the Phase III SOLAR-1 trial evaluating the PI3 kinase inhibitor alpelisib with fulvestrant for ER-positive advanced breast cancer (1:27:4) NEO-ORB: A randomized Phase II study of neoadjuvant letrozole with alpelisib for HR-positive, HER2-negative breast cancer (1:31:47) Select publications  

The Landmarks series continues with Bonadonna's classic adjuvant CMF regimen in breast cancer in a pre-tamoxifen & pre-ER/PR testing era. Discussion points include number needed to treat (NNT) to prevent recurrence and how chlorambucil was considered for the 'C' in CMF.

Maggie Kudirka was a member of the Joffrey Concert Group in NYC when she was diagnosed with stage 4 breast cancer in June 2014. She was only 23 years old and had no risk factors for breast cancer other than being female. Results from a subsequent genetics screening showed that she did not carry the genes linked to breast cancer. Maggie had a large, aggressive tumor that grew very quickly and spread to her bones and lymph nodes. She moved back home to be with her family and began treatment at Mercy Medical Center in Baltimore, Maryland. Fortunately, her type of breast cancer (positive for Her2, ER & PR) responds very well to the drug Herceptin. Maggie's tumor began shrinking after her first chemo treatment on 7/1/14 and continued to shrink until it was completely gone. The pathology report following her double mastectomy on 12/26/14 found no cancer in either breast or lymph nodes. She had a pathological complete response. Six days after surgery, Maggie was back in the studio working to regain my strength, stamina, and technique. Maggie hopes to return to dance in NYC again. Once breast cancer metastasizes to another body part, it is very difficult to know if all the cancer has really left the body after treatment. Tiny, undetectable cancer cells could be lurking dormant in the body. If these cells come to life, the cancer will return. That is why metastatic (stage 4) breast cancer is considered incurable. To keep the cancer cells dormant, Maggie will remain on medications for the rest of her life or until a cure is found. The cost of these medications is enormous: $4,000 to $9,000 per dose, per drug. She receives two drugs every 3 weeks, and a 3rd drug every 4 weeks. Maggie is hoping to join a clinical trial testing a treatment that will keep her cancer from returning. Since the day of her diagnosis, Maggie began spreading the word about metastatic cancer by starting the "Bald Ballerina" campaign.  She now travels the country speaking and teaching to help educate and inspire young dancers.    The costs of battling cancer are enormous even with health insurance which does not cover all expenses. Maggie greatly appreciates donations in any amount for her medical expenses. If you would like to help, tax deductible donations can be made at: http://www.theyoungandbrave.com/warriors/maggie-k/#sthash.NoVcxbRI.dpuf Bald Ballerina Website  BalancingPointe.com   Twitter/Instagram Please leave Rate and Review this show  

ResearchToPractice.com/VPB210 – A 28-yo woman with a 2.5-cm, Grade II, ER/PR+, HER2- breast tumor is enrolled on the BETH trial of adjuvant chemo and trastuzumab with or without bevacizumab. Interview conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPB210 – A 51-yo woman with a 3-cm, Grade II, strongly ER/PR+, HER2- IDC has 17/18 positive axillary nodes and 4 satellite breast nodules. Interview conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPB110 – A 52yo premenopausal woman develops erythematous, ulcerated, ER/PR+, HER2+ BC while receiving AC>TH and tamoxifen for contralateral BC. Interview conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPB110 – A 77yo woman presents with a 10-cm, Grade III, weakly ER/PR+, HER2-equivocal, node+ IDC and questionable liver and bone mets. Interview conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 38-year-old premenopausal woman with a 2-cm, Grade III, ER/PR-positive, HER2-positive IDC and a 1.8-cm, biopsy-confirmed hepatic metastasis. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 47-year-old woman with multiple unresectable brain metastases eight years after adjuvant anthracycline/taxane therapy for an ER/PR-negative, HER2-positive IDC. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 65-year-old woman with rapidly progressive, symptomatic bone and lung metastases after recurrence during her fifth year of an adjuvant aromatase inhibitor for ER/PR-positive, HER2-negative BC. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 62-year-old woman with a neglected 6-cm, ER/PR-positive, HER2-positive IDC and biopsy-proven lung metastases who refuses chemotherapy. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 47-year-old postmenopausal woman with a 1.8-cm, ER/PR-positive, HER2-negative, node-negative BC who developed bone metastases after four years of an adjuvant aromatase inhibitor. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 76-year-old woman with a 0.8-cm, ER/PR-positive, HER2-negative, moderately differentiated IDC with two positive nodes and an Oncotype DX® Recurrence Score® of 13. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 76-year-old woman who underwent a mastectomy for a 6-cm, ER/PR-positive, HER2-positive, T4b IDC with skin ulceration and extensive dermal involvement. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 67-year-old woman with a 2.5-cm, ER/PR-positive, HER2-negative, node-negative IDC who has completed five years of adjuvant anastrozole. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: A 37-year-old woman with a 0.4-cm, moderately differentiated, ER/PR-negative, HER2-positive, node-negative IDC. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 56-year-old premenopausal woman with a 2.2-cm, ER/PR-positive, HER2-negative, node-negative IDC with 88 percent Ki-67. Interviews conducted by Neil Love, MD. Produced by Research To Practice.